Li Liang

机构：The University of Texas MD Anderson Cancer Center, Samil Pharm (South Korea) · ORCID：0000-0002-1694-380X

发表论文 314 篇 · 总被引 6096 次 · h-index 40

代表论文

• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 19)
• Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer (2025 · Critical Reviews in Oncology/Hematology · 被引 15)
• Total glucosides of paeony ameliorates lupus nephritis by suppressing ZBP1-mediated PANoptosis in podocytes (2025 · Phytomedicine · 被引 12)
• Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study (2025 · Signal Transduction and Targeted Therapy · 被引 10)
• Research progress on pathophysiologic mechanisms, clinical treatment and predictive biomarkers in bronchopulmonary dysplasia: from the perspective of oxidative stress (2025 · Frontiers in Pediatrics · 被引 6)
• Peripheral nerve injury-induced remodeling of the tumor-associated macrophages promotes immune evasion in breast cancer (2025 · Journal of Experimental & Clinical Cancer Research · 被引 5)